B7-H1和Bcl-2在上皮性卵巢癌中表达及其临床意义

国际肿瘤学杂志››2015,Vol. 42››Issue (1): 18-21.doi:10.3760/cma.j.issn.1673-422X.2015.01.005

B7-H1和Bcl-2在上皮性卵巢癌中表达及其临床意义

郝志强, 李晓凤, 于德东, 白雪峰

014040包头市中心医院肿瘤科（郝志强、于德东）；包头医学院研究生学院（郝志强）；包头市肿瘤医院肿瘤综合内科（李晓凤），病理科（白雪峰）

收稿日期:2014-06-08修回日期:2014-08-27出版日期:2015-01-08发布日期:2015-01-07
通讯作者:李晓凤 E-mail:btlixiaofeng@126.com
基金资助:

包头市医药卫生科技计划(Wsjj2014031)

Expressions of B7-H1 and Bcl-2 in epithelial ovarian cancer and their clinical significance

Hao Zhiqiang, Li Xiaofeng, Yu Dedong, Bai Xuefeng

Department of Oncology, Baotou Central Hospital; College of Postgraduate, Baotou Medical College, Baotou 014040, China

Received:2014-06-08Revised:2014-08-27Online:2015-01-08Published:2015-01-07
Contact:Li Xiaofeng E-mail:btlixiaofeng@126.com

摘要/Abstract

摘要：目的探讨B7-H1与Bcl-2在上皮性卵巢癌组织中的表达及其与上皮性卵巢癌临床病理特征之间的关系。方法应用免疫组织化学法检测手术切除的80例上皮性卵巢癌组织及20例正常卵巢组织蜡块中B7-H1及Bcl-2的表达情况，并分析其表达与不同临床病理特征之间的相关性。结果上皮性卵巢癌组织B7-H1及Bcl-2阳性表达率分别为77.5%（62/80）和58.8%（47/80），均高于正常卵巢组织的15.0%（3/20）和10.0%（2/20），差异有统计学意义（χ2=27.473，P＜0.05；χ2=15.216，P＜0.05）。Bcl2及B7-H1在上皮性卵巢癌组织中的表达均与分化程度呈负相关（χ2=9.367，P＜0.01；χ2=11.702，P＜0.01），而且Bcl2与国际妇产科联合会分期呈正相关（χ2=7.766，P＜0.01）。另外，在上皮性卵巢癌组织中B7-H1和Bcl-2阳性表达之间呈正相关（r=0.400，P＜0.01）。结论B7H1和Bcl2在上皮性卵巢癌组织中表达明显上调，二者存在正相关性，与上皮性卵巢癌的发生、发展有关，联合检测B7H1和Bcl2可能对上皮性卵巢癌的诊治有一定的指导作用。

关键词:卵巢肿瘤,基因,B7-H1,Bcl-2,免疫组织化学

Abstract:ObjectiveTo investigate the expressions of B7-H1 and Bcl-2 proteins in epithelial ovarian cancer, and to explore the association of the expressions of B7-H1 and Bcl-2 with clinicopathological features. MethodsThe expressions of B7-H1 and Bcl-2 proteins were detected by immunohistochemistry in 80 cases of epithelial ovarian cancer tissues and 20 normal ovary tissues. The association of the expressions of B7H1 and Bcl2 with the clinicopathological features was analyzed. ResultsThe positive expression rates of B7H1 and Bcl2 in epithelial ovarian cancer tissues were 77.5% (62/80) and 58.8% (47/80), both higher than 15.0% (3/20) and 10.0% (2/20) in normal ovary tissues with significant difference （χ2=27.473, P＜0.05; χ2=15.216, P＜0.05）. Both of Bcl2 and B7H1 expressions in epithelial ovarian cancer tissues were negatively correlated with the differentiation degree of epithelial ovarian cancer (χ2=9.367， P＜0.01； χ2=11.702， P＜0.01). The Bcl-2 expression in epithelial ovarian cancer tissues was positively correlated with the FIGO stage (χ2=7.766, P＜0.01). The expression of B7-H1 was positively correlated with the expression of Bcl2 in epithelial ovarian cancer (r=0.400, P＜0.01). ConclusionThe expressions of B7-H1 and Bcl-2 are upregulated in epithelial ovarian cancer and they correlate to each other positively. The expressions of B7-H1 and Bcl-2 are correlated with the invasion and metastasis of epithelial ovarian cancer. The detection of B7-H1 combined with Bcl-2 may have an important clinical significance in the diagnosis and treatment for patients with epithelial ovarian cancer.

Key words:Ovarian neoplasms,Gene,B7-H1,Bcl-2,Immunohistochemistry

郝志强, 李晓凤, 于德东, 白雪峰. B7-H1和Bcl-2在上皮性卵巢癌中表达及其临床意义[J]. 国际肿瘤学杂志, 2015, 42(1): 18-21.

Hao Zhiqiang, Li Xiaofeng, Yu Dedong, Bai Xuefeng. Expressions of B7-H1 and Bcl-2 in epithelial ovarian cancer and their clinical significance[J]. Journal of International Oncology, 2015, 42(1): 18-21.

参考文献

［1］ Dong H, Zhu G, Tamada K, et al. B7H1, a third member of the B7 family, costimulates Tcell proliferation and interleukin10 secretion［J］. Nat Med, 1999, 5(12): 1365-1369. ［2］ Bigelow E, Bever KM, Xu H, et al. Immunohistochemical staining of B7H1 (PDL1) on paraffinembedded slides of pancreatic adenocarcinoma tissue［J］. J Vis Exp, 2013, 71: 4059. ［3］ Hua D, Sun J, Mao Y, et al. B7H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma［J］. World J Gastroenterol, 2012, 18(9): 971978. ［4］ Muller CY. Doctor, should I get this new ovarian cancer testOVA1?［J］. Obstet Gynecol, 2010, 116 (2 Pt 1): 246-247. ［5］ Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer［J］. Proc Natl Acad Sci USA, 2007, 104(9): 33603365. ［6］ Azuma T, Yao S, Zhu G, et al. B7H1 is a ubiquitous antiapoptotic receptor on cancer cells［J］. Blood, 2008, 111(7): 3635-3643. ［7］ Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigenspecific CD8 T cells infiltrating the tumor express high levels of PD1 and are functionally impaired［J］. Blood, 2009, 114(8): 1537-1544. ［8］ Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7H1 is associated with poor prognosis in renal cell carcinoma patients with longterm followup［J］. Cancer Res, 2006, 66(7): 3381-3385. ［9］ Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death1 ligand1 and programmed death1 ligand2 expression in human esophageal cancer［J］. Clin Cancer Res, 2005, 11(8): 2947-2953. ［10］ Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy［J］. Oncogene, 2007, 26(9): 1324-1337. ［11］ Li P, Zhang ST, Yu ZL, et al. Effects of cyclooxygenase2 nonselective and selective inhibitors on proliferation inhibition and apoptosis induction of esophageal squamous carcinoma cells［J］. Dis Esophagus, 2009, 22(1): 2131. ［12］ Anderson NS, Turner L, Livingston S, et al. Bcl2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation［J］. J Ovarian Res, 2009, 2: 16. ［13］ Kang MH, Reynolds CP. Bcl2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy［J］. Clin Cancer Res, 2009, 15(4): 1126-1132. ［14］ Zhang Z, Wu G, Gao J, et al. Inclusion complex of a Bcl2 inhibitor with cyclodextrin: characterization, cellular accumulation, and in vivo antitumor activity［J］. Mol Pharm, 2010, 7(4): 1348-1354. ［15］ Avraam K, Pavlakis K, Papadimitriou C, et al. The prognostic and predictive value of ERCC1, p53, bcl2 and bax in epithelial ovarian cancer［J］. Eur J Gynaecol Oncol, 2011, 32(5): 516-520.

[1]	龚艳, 陈洪雷.微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[2]	安荣, 刘美华, 王佩晨, 王晓慧.Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[3]	吴佳丽, 张佳慧, 张萍, 肖昕悦, 李睿, 张红宇.Bcl-2 BH4选择性抑制剂BDA-366抑制NK/T细胞淋巴瘤细胞的机制研究[J]. 国际肿瘤学杂志, 2023, 50(7): 413-418.
[4]	李晨曦, 赵宏伟.二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[5]	李彬, 张桂芳, 周林静, 杨小冬, 何秋立, 贾思思, 黄普超, 梁嘉欣.三阴性乳腺癌中PIK3CA基因状态与临床特征及预后的关系[J]. 国际肿瘤学杂志, 2023, 50(5): 263-267.
[6]	刘博翰, 黄俊星.溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[7]	杨丽蓉, 王羽丰.预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[8]	廖利华, 王少洪, 陈洪才, 赵勇强.细胞蜡块免疫组织化学与胸腔积液CRKL、MIC-1诊断恶性胸腔积液的价值[J]. 国际肿瘤学杂志, 2023, 50(2): 71-75.
[9]	刘玉杰, 赵志强, 王子琤.早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[10]	邓莉莉, 段星宇, 李保中.HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[11]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦.伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[12]	曹纯, 曾琴, 张天围.头颈部滑膜肉瘤1例[J]. 国际肿瘤学杂志, 2023, 50(1): 60-61.
[13]	张子悦, 郑斯豪, 高彦君, 姚颐, 宋启斌.基于CRISPR/Cas9的基因编辑技术及其在肿瘤治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 546-549.
[14]	黎立喜, 温霆宇, 管秀雯, 翟婧彤, 马飞.早发性乳腺癌的遗传易感基因及临床特征[J]. 国际肿瘤学杂志, 2022, 49(4): 206-209.
[15]	李杨仪, 龚龑, 谢丛华.SAMHD1抑制肺腺癌细胞中PD-L1表达的研究[J]. 国际肿瘤学杂志, 2022, 49(11): 658-664.